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M. M. Hitzert1*, S. N. van der Crabben2, G. Baldewsingh3, H. K. Ploos van Amstel2, A. van den Wijngaard4,
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Abstract
Background: Mandibuloacral Dysplasia with type B lipodystrophy (MADB) is a rare premature aging disorder with
an autosomal recessive inheritance pattern. MADB is characterized by brittle hair, mottled, atrophic skin, generalized
lipodystrophy, insulin resistance, metabolic complications and skeletal features like stunted growth, mandibular and
clavicular hypoplasia and acro-osteolysis of the distal phalanges. MADB is caused by reduced activity of the enzyme
zinc metalloprotease ZMPSTE24 resulting from compound heterozygous or homozygous mutations in ZMPSTE24.
Methods: In 2012, and again in 2018, eight related patients from the remote tropical rainforest of inland Suriname
were analysed for dysmorphic features. DNA analysis was performed and clinical features were documented. We
also analysed all previously reported genetically confirmed MADB patients from literature (n = 12) for their clinical
features. Based on the features of all cases (n = 20) we defined major criteria as those present in 85–100% of all
MADB patients and minor criteria as those present in 70–84% of patients.
Results: All the Surinamese patients are of African descent and share the same homozygous c.1196A > G,
p.(Tyr399Cys) missense variant in the ZMPSTE24 gene, confirming MADB. Major criteria were found to be: short
stature, clavicular hypoplasia, delayed closure of cranial sutures, high palate, mandibular hypoplasia, dental
crowding, acro-osteolysis of the distal phalanges, hypoplastic nails, brittle and/or sparse hair, mottled pigmentation,
atrophic and sclerodermic skin, and calcified skin nodules. Minor criteria were (generalized or partial) lipoatrophy of
the extremities, joint contractures and shortened phalanges. Based on our detailed clinical observations, and a
review of previously described cases, we propose that the clinical diagnosis of MADB is highly likely if a patient
exhibits ≥4 major clinical criteria OR ≥ 3 major clinical criteria and ≥ 2 minor clinical criteria.
Conclusions: We report on eight related Surinamese patients with MADB due to a homozygous founder mutation
in ZMPSTE24. In low-income countries laboratory facilities for molecular genetic testing are scarce or lacking.
However, because diagnosing MADB is essential for guiding clinical management and for family counselling, we
defined clinical diagnostic criteria and suggest management guidelines.
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Introduction
Mandibuloacral Dysplasia with type B lipodystrophy
(MADB) is a rare premature aging disorder (OMIM #
608612) with and autosomal recessive inheritance pat-
tern. It is characterized by brittle or absent hair, mottled
and atrophic skin, generalized lipodystrophy, insulin re-
sistance, teeth abnormalities, metabolic complications
and skeletal features like stunted growth, mandibular
and clavicular hypoplasia and acro-osteolysis of the dis-
tal phalanges [1]. Renal [2–4], cardiac and muscle in-
volvement [4] have been described in some patients. The
first clinical signs of MADB may be apparent at birth
[3]. MADB patients’ cognition and social behaviour are
usually normal. Diagnosis of MADB is based on history,
physical examination, body composition and metabolic
status. As yet, no clinical diagnostic criteria have been
established [5], although Haye and colleagues [6] consid-
ered failure of ossification of the interparietal region of
the occipital bone as a possible pathognomonic sign for
MADB. Molecular genetic testing can confirm a diagno-
sis of MADB in most cases.
MADB is caused by reduced activity of the enzyme
zinc metalloprotease ZMPSTE24 as a result of com-
pound heterozygous or homozygous mutations in
ZMPSTE24 located on chromosome 1p34. A normal
level of zinc metalloprotease is necessary to cleave the
prenatylated and carboxylated 15-amino acid tail from
the C-terminus of prelamin A to yield mature lamin A.
The decreased function of zinc metalloprotease
ZMPSTE24 leads to an abnormal accumulation of lamin
A precursors. Mature lamin A, together with the B-type
lamin and lamin C, is mandatory for providing the
shape, structure and function of the nuclear lamina [7].
ZMPSTE24 mutations leading to a complete loss of en-
zyme activity are associated with the lethal syndrome re-
stricted dermopathy (RD, OMIM #275210) [8]. The
more common Mandibuloacral Dysplasia with type A
lipodystrophy (MADA; OMIM #248370) shares features
with MADB, but is characterized by partial lipodystro-
phy of the extremities. MADA is caused by mutations in
LMNA located on chromosome 1q22, leading to unpro-
cessed lamin A [8].
To date, 12 genetically confirmed MADB patients have
been reported in literature [1, 3, 4, 6, 9–14]. Here we present
eight related patients of African descent from the remote
tropical rainforest of inland Suriname with MADB caused by
a homozygous pathogenic missense variant in ZMPSTE24.
This variant has previously been reported in another patient
with MADB, is located in a highly conserved area across spe-
cies, predicted to be probably damaging (by prediction pro-
grammes such as SIFT and Polyphen) and has so far not
been reported in gnomAD [6]. Our clinical description of
MADB in this related family clearly depicts the phenotypic
spectrum across different ages.
No clinical diagnostic criteria for MADB have been
established thus far, but such criteria could be useful in
remote areas in the absence of laboratory diagnostic pos-
sibilities. Establishing a diagnosis is essential for guiding
clinical management and counselling patients and their
family members. We therefore propose clinical diagnos-
tic criteria and management guidelines based on the fea-
tures found in our patients and previously reported
MADB patients.
Patients and methods
In 2012, and again in 2018, patients were referred to the
clinical geneticist in the outpatient clinic for diagnostic
work-up because of unexplained dysmorphic features
and painful feet, which had been diagnosed previously
by medical doctors of the Medical Mission Primary
Health Care Suriname (MM).
Patients
In 2012 the first six patients with dysmorphic features
and painful feet were medically examined as part of the
Medical Mission Primary Health Care Suriname pro-
gram. The examination took place in an outpatient clinic
in inland Suriname. Diagnostic genetic testing was per-
formed after written informed consent from the patients
or their legal representatives in accordance with local
regulations. In 2018, the patients were invited to the de-
partment of Paediatrics of the Diakonnessenhuis hospital
in Paramaribo for follow-up. For the calculation of
standard deviations of height, weight for height and head
circumference we used the growth curves of the TNO
(Dutch organization for applied scientific research) [15].
Literature analysis of previous published patients was
performed to establish phenotypic features. We system-
atically searched the PubMed database using the terms
‘Mandibuloacral dysplasia’ AND ‘ZMPSTE24’. We lim-
ited our search to full-text articles published in English
and refined our search results by selecting only those ar-
ticles that report on patients in whom MADB was genet-
ically confirmed. We used the most recently published
review article [16] to confirm that we had included all
genetically confirmed MADB cases.
Genetic testing
Genetic testing was performed in the Clinical Genetics
laboratory of the University Medical Centre Utrecht.
DNA was isolated from peripheral lymphocytes using
standard procedures. First, the LMNA gene was se-
quenced in one patient and no likely pathogenic or
pathogenic variant was identified. Hereafter, the
ZMPSTE24 gene was analysed, which revealed a homo-
zygous missense variant that was classified as likely
pathogenic by analysis in the Alamut Vision (v.2.11) mu-
tation interpretation software program using e.g. SIFT,
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PolyPhen-2, GERP and Grantham scores and because of
its absence in the Genome Aggregation Database (Gno-
mADvs2.1). Subsequently, targeted mutation analysis
was performed in the other affected family members.
Phenotypic analyses
For each patient, the presence or absence of possible
MADB features was documented. Possible MADB fea-
tures were defined as clinical features noted more than
once in MADB patients in the literature and more than
once in the current cohort. The prevalence of each cri-
terion was calculated by dividing the number of patients
positive for that criterion by the number for whom that
criterion was documented. In the absence of a gold
standard for setting clinical criteria, we defined major
criteria as clinical features present in 85–100% of all re-
ported MADB patients. Minor criteria were defined as
clinical features present in 70–84% of all reported
MADB patients. Criteria that might be causally related,
such as high palate, mandibular hypoplasia and dental
crowding, were clustered. We also clustered hypoplastic
nails and brittle or sparse hair since nail and hair abnor-
malities both represent ectodermic abnormalities. Skin
abnormalities were clustered into one major criterion
since all MADB patients showed two or more skin ab-
normalities. To determine cut-off points for establishing
a clinical diagnosis of MADB we chose a combination of
major and minor clinical features that applied to all
MADB patients from our cohort and to most previously
reported MADB patients.
Follow-up data were available for six patients, includ-
ing blood glucose levels and blood pressure measure-
ments. Based on the observations in our cohort we
proposed management guidelines.
Results
Sequence analysis of the ZMPSTE24 gene revealed a pre-
viously documented [6] homozygous likely pathogenic
mutation NM_005857.3: c.1196A >G, p.(Tyr399Cys)
(OMIM#606480). Segregation of this variant was
confirmed by targeted mutation analyses in seven other
affected family members, thereby confirming its pathogen-
icity. A detailed clinical description of each patient is pre-
sented in Tables 1 and 2. A pedigree is shown in Fig. 1.
See Fig. 2 for photographic images of the individual
MADB patients.
Patients ranged in age from 3 to 41 years. All patients
from our cohort had a short stature, clavicular hypopla-
sia, delayed closure of cranial sutures, an underdevel-
oped occipital bone, acro-osteolysis of the distal
phalanges, short phalanges of the hands, hypoplastic
nails, a high palate, dental crowding, brittle and/or
sparse hair and skin features (see Table 2 for details).
Loss of subcutaneous fat from the palms of the hands
and soles of the feet was noted in (nearly) all patients
(see Table 2). The eldest patient had calcified nodules
on the skin of her hands and arms. Patients IV, VII and



















Birth data median (range)
Gender (male/female) male female female male female female male female 3/5
Birth weight (grams) 2880 2700 1830 2110 1830 1840 ? 2180 2110 (1830–2880)
Birth weight (percentile) p5-p15 p5-p15 <p1 <p1 <p1 <p1 ? <p1
Height (cm) 45 48 43 43 ? 41 ? ? 43 (41–48)
Height (percentile) <p1 p25-
p50
<p1 <p1 ? <p1 ? ?
Head circumference (cm) 33 30 30 ? ? 33 ? ? 31.5 (30–33)
Head circumference (percentile) p5-p15 <p1 <p1 ? ? p15-p25 ? ?
Growth parameters at 1st examination
Age in years (y), months (m) 3y, 2 m 6y, 9 m 11y, 8 m 21y 21y 24y 36y 41y 21y (3–41)
Height (cm) 84 106.5 132 145 134 133 142 132
Height-for-age (standard deviation) −4.0 −3.0 −2.5 −5.0 −6.0 −6.2 −5.5 − 6.3
Weight (kg) ? 15.3 26.8 40.6 28.4 39.1 32.2 34.1
Weight-for-height (standard deviation) ? −1.0 0.0 + 1.8 + 0.2 + 2.5 0.0 + 1.8
Head circumference (cm) 45.4 49.5 48.5 54 50 52.8 52 48.5
Head circumference-for-age (standard
deviation)
−3.0 −1.0 −3.0 −2.0 −3.0 − 1.5 − 3.0 −3.7
? = not assessed
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literature (n = 12)
total of MADB







yes yes no yes yes yes yes yes 7/8 (88) 7/11 (64) 14/19 (74)
Truncal
lipoatrophy
yes yes no no yes yes yes ? 5/7 (71) 5/10 (50) 10/17 (59)
Generalized
lipodystrophy
yes yes no yes yes yes yes ? 6/7 (86) 4/11 (36) 10/18 (56)
Facial
lipoatrophy
yes no no yes yes yes yes yes 6/8 (75) 4/12 (36) 10/20 (50)
Skeletal features
Short stature yes yes yes yes yes yes yes yes 8/8 (100) 10/10 (100) 18/18 (100)
Underdeveloped
occipital bonea
yes yes yes yes yes yes yes yes 7/7 (100) 2/2 (100) 9/9 (100)
Hypoplastic nails yes yes yes yes yes yes yes yes 8/8 (100) 7/7 (100) 15/15 (100)
Acro-osteolysis of
distal phalangesb
yes yes yes yes yes yes yes yes 8/8 (100) 11/12 (92) 19/20 (95)
Delayed closure
of cranial sutures
? yes ? yes yes yes possible ? 5/5 (100) 9/10 (90) 14/15 (93)
Mandibular
hypoplasia
yes no yes yes no yes yes yes 6/8 (75) 12/12 (100) 18/20 (90)
Clavicular
hypoplasiac




yes yes yes yes yes yes yes yes 8/8 (100) 7/11 (64) 15/19 (79)
Joint
contractures
no no no yes yes yes yes yes 5/8 (63) 9/12 (82) 14/20 (70)
Facial features
High palate yes yes ? yes yes yes ? yes 6/6 (100) 3/3 (100) 9/9 (100)
Pinched nose yes no no no no/
bifid
yes yes ? 3/7 (43) 9/11 (82) 12/18 (67)
Proptosis no no no yes yes yes no no 3/8 (38) 7/10 (70) 10/18 (56)
Posteriorly
rotated ears
yes no no no yes yes yes yes 5/8 (63) 3/7 (43) 8/15 (53)
Gaze palsy and/
or ptosis
no no no no no no yes
(ptosis)
no 1/8 (13) 1/4 (25) 2/12 (17)
Tooth abnormalities
Dental crowding yes yes yes yes yes yes yes yes 8/8 (100) 6/7 (86) 14/15 (93)
Hypoplastic
teeth




yes yes yes yes yes yes yes yes 8/8 (100) 9/12 (75) 17/20 (85)




yes yes yes yes yes yes yes yes 8/8 (100) 10/10 (100) 18/18 (100)
Skin atrophy yes yes yes yes yes yes yes yes 8/8 (100) 11/11 (100) 19/19 (100)
Sclerodermic skin yes yes yes yes yes yes yes yes 8/8 (100) 8/9 (89) 16/17 (94)
Calcified skin yes yes yes yes yes yes yes yes 8/8 (100) 5/7 (71) 13/15 (87)
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VIII had developed contractures of the fingers and toes.
All patients showed normal psychomotor development.
Follow-up data are available for six patients (patients I, II,
III, VI, VII and VIII) with patients III, IV and V lost to
follow-up. Patient VIII died from heart failure at the age
of 44 years. An X-ray demonstrated an enlarged heart in
patient VIII and no additional cardiological evaluation was
performed. None of the living patients developed diabetes
mellitus. Patients VI and VII developed hypertension for
which antihypertensive medication was started. Patient
VII is suffering from dyspnoea and peripheral edema asso-
ciated with his cardiac failure and will be evaluated by the
cardiologist. Female patients did not report abnormalities
of their period and were able to have normal reproduction
(so far). See Table 2 for the clinical features of previously
reported MADB patients.
Based on the prevalence of the clinical features as
listed in Table 2, we defined major and minor clinical
criteria (Table 3). We suggest that patients should ex-
hibit ≥4 major clinical features OR ≥ 3 major clinical fea-
tures and ≥ 2 minor clinical features in order to make
the clinical diagnosis of MADB. All genetically proven
MADB patients from our cohort fulfilled the diagnosis
of MADB. In two out of the twelve MADB cases from
the literature, an occipital ossification defect was re-
ported [6, 12]. In the other ten MADB patients there
was no information available on occipital ossification de-
fects. All these ten MADB cases did exhibit ≥4 major
clinical features OR ≥ 3 major clinical features.
When we applied our clinical criteria to fourteen
typical MADA patients with a proven LMNA muta-
tion, they also fulfilled the criteria. The only discrim-
inating feature between the MADA patients and the
MADB patients is the occipital ossification defect,
present in MADB patients only. One MADA patient
(10 months old) exhibited only three major and one























literature (n = 12)
total of MADB





yes yes yes yes yes yes ? yes 7/7 (100) 7/9 (78) 14/16 (88)
Major / minor
criteria (n/n)#
6/2 7/2 5/1 7/3 7/3 7/3 5/3 6/3
? = not assessed. Short stature is defined as a length below the third percentile. No phenotypic data are available for two patients [8]. These
patients are not included in this table
abased on physical examination: a palpable defect at the level of the occipital bone. For one patient (patient III), an X-ray of the skull
was available
b based on physical examination: presence of club-shaped digit(s) and/or prominent interphalangeal joints. For one patient (patient III), an X-ray
of the hands was available
c based on physical examination
# see Table 3 for the definition of major and minor criteria
Fig. 1 Pedigrees and pictures of the individuals studied. a Pedigree of the eight MADB patients suggestive of a common ancestor. Black boxes
indicate affected individuals. White boxes with a dot are presumed heterozygous carriers of MADB. Roman numerals indicating the individual are
plotted below each pedigree symbol
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minor criteria and therefore did not fulfil the clinical
criteria [17].
Once a diagnosis of MADB is considered, we recom-
mend performing several evaluations based on the obser-
vations in our cohort (Table 4). Skeletal X-rays to evaluate
for characteristic findings are not necessarily needed, but
could guide in the diagnosis of MADB. Consultation with
a clinical geneticist and/or genetic counsellor is recom-
mended. When no genetic counsellor is available, the
patient and/or the parents should be informed about the
25% risk of siblings of the patient having the same condi-
tion. Once the pathogenic variant has been identified in
an affected family member, prenatal testing for a preg-
nancy at increased risk and preimplantation genetic diag-
nosis are possible (only available in some countries).
Preventive measurements include a regular healthy diet
and shoe pads, or at least comfortable footwear, because
lack of body fat may lead to painful feet.
Fig. 2 Images of individuals with MADB at chronological ages. Photographic images of a total body showing typical lipodystrophy; b facial
features showing facial lipoatrophy, and mandibular hypoplasia; c oral region and teeth showing dental crowding, high palate; d skin showing
calcified skin nodules and mottled, sclerodermic and atrophic skin in from left to right: patient, abdomen, legs (patient III, IV), arms (patients IV, V,
IV, VI, VII) and abdomen e skull showing brittle and/or sparse hair; f hands and g feet showing acro-osteolysis of distal phalanges, shortened
phalanges, joint contractures, hypoplastic nails, palmar and plantar atrophy of the hand and feet and calluses. X-rays of patient III showing h acro-
osteolysis of the distal phalanges and i diminished occipital ossification (indicated by white arrows)
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Discussion
We describe eight related patients from remote inland
Suriname with MADB due to the same homozygous
likely pathogenic variant in the ZMPSTE24 gene. In
2016, Haye and colleagues [6] described a male MADB
patient carrying the same homozygous variant and that
patient’s parents originated from the same tribal com-
munity as the patients in our cohort. It is therefore likely
that Haye et al.’s patient shares the same ancestor as our
patients, suggesting the existence of a founder mutation.
We classified the variant in our cohort as patho-
genic based on prediction programmes (e.g. SIFT,
PolyPhen), because of its absence in gnomADvs2.1,
segregation of this variant in all affected family
members, and because of clinical features that fit with
the diagnosis of MADB.
The MADB patient described by Haye et al. [6] shows
striking similarities to our patients: short stature, micro-
cephaly, mandibular hypoplasia, sparse hair, mottled and
atrophic skin, short phalanges of the hands with acro-
osteolysis, delayed closure of cranial sutures and ossifica-
tion failure of the occipital bone. Ossification failure of
the occipital bone has also been observed in another
MADB patient [12]. Haye et al. suggested that this fea-
ture might be a clinically diagnostic sign for MADB. In
line with this, the occipital bone was underdeveloped in
all of our patients. For one patient, an X-ray of the skull
was available. In the other six patients a defect at the
level of the occipital bone was clearly palpable. No ossifi-
cation defect has been noted in other unaffected family
members of this tribe. Our findings supports Haye
et al.’s proposition that ossification failure of the occipi-
tal bone might be regarded an important clinical sign for
MADB. Ossification defect of the occipital bone (without
ossification defects of other cranial bones) is very un-
common and has not been linked to other diseases thus
far. It has neither been linked to MADA patients, lead-
ing us to consider an occipital ossification defect as a
pathognomonic feature distinguishing MADA from
MADB patients. Based on the present literature we can,
however, not exclude the presence of occipital ossifica-
tion defects in MADA patients since radiographic exam-
inations of the skull were only performed in six out of
the fourteen MADA patients [10, 18–21]. In addition,
given the high consanguineous rate in our pedigree and
the fact that, due to costs and diagnostic setting no
whole exome sequencing has been performed, a second
underlying genetic condition responsible for the occipital
defects in our cohort cannot be ruled out. Therefore it
seems premature to include the failure of ossification of
the occipital bone as a major diagnostic criterium yet.
Future reports on skull defects in MADA and MADB
Table 3 Proposed diagnostic criteria for MADB
Presence of ≥4 major clinical criteria OR presence of ≥3 major clinical
criteria and≥ 2 minor clinical criteria
Major criteriaa Minor criteriab
- short stature (height < 2 standard
deviations)
- (generalized or partial)
lipoatrophy of the extremities
- clavicular hypoplasia - joint contractures
- delayed closure of cranial sutures - shortened phalanges
- high palate and/or mandibular
hypoplasia and/or dental crowding
- acro-osteolysis of distal phalanges
(hands and/or feet)
- hypoplastic nails and/or brittle or
sparse hair






a present in 85–100% of reported MADB patients
b present in 70–84% of reported MADB patients
Table 4 Recommended evaluations in MADB patients
Evaluation First evaluation Frequency
Blood glucose level; evaluation of diabetes mellitus following initial
diagnosis
annually
Blood pressure measurement; evaluation of renal failure following initial
diagnosis
annually
Urine protein and glucose levels; evaluation of renal failurea following initial
diagnosis
annually





Dental examination; extraction of primary teeth may be required to avoid crowding and development of two
rows of teeth
around the age of 4
years
annually
Blood lipid profiles; abnormal levels requires treatment including exercise, diet modification, and medication as
warranted
around the age of 20
years
annually
a This can be monitored by dipstick urine analysis
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patients are required to further underline that occipital
ossification defects might be regarded a pathognomonic
sign in MADB patients.
In contrast to the patient reported by Haye et al. [6], the
patients in our cohort did not have gaze palsy and ptosis was
noted in only one patient. Gaze palsy and ptosis might thus
have been a coincidental finding in the patient described by
Haye et al. and not a true clinical feature of MADB.
All of our patients had a normal psychomotor devel-
opment. It has been suggested that the central nervous
system is spared in patients with LMNA-linked disorders
via downregulation of LMNA transcripts in the brain
[22]. The ZMPSTE24 gene mutated in MADB patients
encodes the zinc metalloprotease enzyme involved in
production of mature lamin A. We therefore hypothesize
that downregulation of LMNA transcripts in the brain
might also explain the lack of neurodevelopmental dis-
abilities in MADB patients.
Our longitudinal cohort shows variable phenotypes across
ages, and we observed that some clinical features of MADB
developed over time. For example, our three youngest pa-
tients (examined at the ages of 3, 6 and 11 years, respect-
ively) did not have joint contractures, proptosis, alopecia, or
(marked) facial lipoatrophy. Still, those patients fulfilled the
clinical diagnosis of MADB based on our proposed criteria
of ≥4 major clinical features OR ≥ 3 major clinical features
and ≥ 2 minor clinical features (Table 3). Only one previ-
ously published 9-month-old patient did not fulfil our
MADB criteria [11]. He showed three major features: short
stature, mandibular hypoplasia and skin abnormalities (i.e.
atrophic and sclerodermic skin and mottled pigmentation).
No minor features were present in this patient, indicating
that in very young children the diagnosis might be missed.
For instance, the major features delayed closure of cranial
sutures and dental crowding cannot be assessed at a very
young age. Thus re-evaluation should be performed when
children grow older. However, the absence of several MADB
features in the 9-month-old patient [11] might also be due
to his limited clinical description. In a previously reported
10-month-old patient MADB could be diagnosed based on
the presence of five major features, i.e. mandibular hypopla-
sia, clavicular hypoplasia, acro-osteolysis of distal phalanges,
hypoplastic nails and skin abnormalities (atrophic skin and
mottled pigmentation) and three minor features, i.e. lipoa-
trophy of the extremities, shortened phalanges and joint
contractures [13]. Information on occipital ossification de-
fects was, however, not available. It might also be that some
publications may not have mentioned the presence or ab-
sence of certain features. Based on the current cohort and
previously published MADB patients, we suggest that our
MADB criteria can be used even in young patients, prefera-
bly from the age of 10months onwards. These criteria will
also help to evaluate if additional features, currently missing
in the diagnostic criteria, need to be added, In addition more
clinical data is needed to evaluate whether there is a
genotype-phenotype correlation and if patients with MADB
based on compound heterozygosity of a missense and a null
mutation in the ZMPSTE24-gene may have a more severe
phenotype than patients who have homozygous misssense
mutations in this gene.
Children in low-income countries with limited access to
genetic testing, in particular, could benefit from being diag-
nosed with MADB based on clinical criteria because it
might guide clinical management. This is especially import-
ant because several complications are reported in MADB
patients, including impaired glucose tolerance [23], diabetes
mellitus [2, 23], glomerulopathy [1, 2] and vascular compli-
cations such as high blood pressure and atherosclerosis [2,
4]. In our population, patients complained about painful
feet due to plantar atrophy of their feet. This can lead to
wounds and, in combination with diabetes mellitus, might
develop into extensive infections, making early diagnosis
crucial in preventing these complications.
One of our patients died from heart failure. Since add-
itional cardiological evaluation or autopsy was not per-
formed, we can only speculate about the underlying
cause. Important to mention is that there were no signs
of renal failure. Patient VII is suffering from symptoms
associated with cardiac failure. He is awaiting cardiac evalu-
ation. Myocardial pathology has not been reported before
in MADB patients [16]. Dilated cardiomyopathy has how-
ever been reported in ZMPSTE24-deficient mice [24–26].
Whether the heart failure in our patient is a solitary finding
or this should be regarded part of mandibuloacral dysplasia
requires further reports on MADB patients.
One of the limitations of our study is that additional in-
vestigations such as measuring blood and urine samples
or performing X-rays could not be performed in most pa-
tients due to the limited availability of medical facilities.
Secondly, the cause of death in one patient was uncertain
but probably due to cardiac failure. Finally, although our
clinical diagnostic criteria apply to most MADB patients
they might not detect all MADB patients, especially those
who are very young. Close follow-up of patients suspected
of MADB, is therefore warranted.
Conclusions
In this study, we report on eight related Surinamese pa-
tients with MADB due to a homozygous founder muta-
tion in the ZMPSTE24 gene. Our data illustrate the full
phenotypic spectrum of MADB associated with a homozy-
gous ZMPSTE24 mutation. We propose clinical criteria
for MADB that may be of use in settings with limited or
no access to genetic testing. Future clinical research in
MADB patients is needed to further refine our proposed
clinical criteria because early diagnosis is essential for
guiding clinical management and for family counselling.
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